Sumitomo Mitsui DS Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.53M | Buy |
18,366
+2,423
| +15% | +$731K | 0.04% | 322 |
|
|
2026
Q1 | $5.28M | Buy |
15,943
+74
| +0.5% | +$25.2K | 0.04% | 308 |
|
|
2025
Q4 | $6.31M | Buy |
15,869
+43
| +0.3% | +$19K | 0.05% | 262 |
|
|
2025
Q3 | $7.22M | Buy |
15,826
+1,018
| +7% | +$415K | 0.06% | 244 |
|
|
2025
Q2 | $4.83M | Buy |
14,808
+1,851
| +14% | +$512K | 0.04% | 312 |
|
|
2025
Q1 | $3.5M | Buy |
12,957
+1,346
| +12% | +$346K | 0.04% | 367 |
|
|
2024
Q4 | $2.73M | Buy |
11,611
+30
| +0.3% | +$7.89K | 0.03% | 418 |
|
|
2024
Q3 | $3.19M | Sell |
11,581
-533
| -4% | -$139K | 0.03% | 376 |
|
|
2024
Q2 | $2.94M | Buy |
12,114
+2,619
| +28% | +$413K | 0.03% | 365 |
|
|
2024
Q1 | $1.42M | Sell |
9,495
-28
| -0.3% | -$4.67K | 0.02% | 526 |
|
|
2023
Q4 | $1.82M | Hold |
9,523
| – | – | 0.02% | 474 |
|
|
2023
Q3 | $1.69M | Sell |
9,523
-26
| -0.3% | -$4.96K | 0.03% | 441 |
|
|
2023
Q2 | $1.81M | Buy |
9,549
+1,259
| +15% | +$250K | 0.03% | 428 |
|
|
2023
Q1 | $1.66M | Hold |
8,290
| – | – | 0.03% | 421 |
|
|
2022
Q4 | $1.97M | Hold |
8,290
| – | – | 0.04% | 355 |
|
|
2022
Q3 | $1.66M | Buy |
8,290
+1,178
| +17% | +$225K | 0.04% | 371 |
|
|
2022
Q2 | $1.04M | Hold |
7,112
| – | – | 0.02% | 480 |
|
|
2022
Q1 | $1.16M | Sell |
7,112
-34
| -0.5% | -$5.18K | 0.02% | 482 |
|
|
2021
Q4 | $1.21M | Buy |
7,146
+1,197
| +20% | +$222K | 0.03% | 486 |
|
|
2021
Q3 | $1.12M | Sell |
5,949
-80
| -1% | -$15K | 0.03% | 473 |
|
|
2021
Q2 | $1.02M | Sell |
6,029
-28
| -0.5% | -$4.1K | 0.02% | 503 |
|
|
2021
Q1 | $855K | Buy |
6,057
+2
| +0% | +$301 | 0.02% | 526 |
|
|
2020
Q4 | $786K | Hold |
6,055
| – | – | 0.02% | 526 |
|
|
2020
Q3 | $881K | Hold |
6,055
| – | – | 0.03% | 448 |
|
|
2020
Q2 | $896K | Buy |
6,055
+7
| +0.1% | +$944 | 0.03% | 421 |
|
|
2020
Q1 | $658K | Buy |
6,048
+35
| +0.6% | +$4.04K | 0.03% | 436 |
|
|
2019
Q4 | $692K | Hold |
6,013
| – | – | 0.02% | 518 |
|
|
2019
Q3 | $483K | Buy |
6,013
+1,803
| +43% | +$143K | 0.02% | 566 |
|
|
2019
Q2 | $305K | Sell |
4,210
-15,833
| -79% | -$1.21M | 0.01% | 641 |
|
|
2019
Q1 | $1.87M | Sell |
20,043
-1,462
| -7% | -$122K | 0.03% | 365 |
|
|
2018
Q4 | $1.57M | Buy |
21,505
+2,120
| +11% | +$163K | 0.03% | 356 |
|
|
2018
Q3 | $1.7M | Sell |
19,385
-47
| -0.2% | -$4.73K | 0.03% | 398 |
|
|
2018
Q2 | $1.91M | Buy |
19,432
+13,877
| +250% | +$1.38M | 0.03% | 368 |
|
|
2018
Q1 | $661K | Sell |
5,555
-63
| -1% | -$8.12K | 0.01% | 615 |
|
|
2017
Q4 | $713K | Buy |
+5,618
| New | +$706K | 0.01% | 618 |
|
|
2016
Q4 | – | Sell |
-5,284
| Closed | -$358K | – | 754 |
|
|
2016
Q3 | $358K | Hold |
5,284
| – | – | 0.01% | 681 |
|
|
2016
Q2 | $293K | Buy |
5,284
+160
| +3% | +$10.1K | 0.01% | 673 |
|
|
2016
Q1 | $321K | Buy |
5,124
+49
| +1% | +$3.26K | 0.01% | 665 |
|
|
2015
Q4 | $477K | Hold |
5,075
| – | – | 0.02% | 599 |
|
|
2015
Q3 | $407K | Sell |
5,075
-300
| -6% | -$33.3K | 0.01% | 627 |
|
|
2015
Q2 | $644K | Buy |
+5,375
| New | +$642K | 0.02% | 557 |
|
Other funds holding ALNY
Sumitomo Mitsui DS Asset Management's ALNY Position: Q2 2026 in Review
Sumitomo Mitsui DS Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, buying an estimated $731K and bringing the position to 18,366 shares worth $5.53M. The position accounts for 0.04% of the portfolio, ranked #322.
Sumitomo Mitsui DS Asset Management first reported a position in ALNY in Q2 2015 and has held it in 41 quarters since. The position peaked at $7.22M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Sumitomo Mitsui DS Asset Management held 18,366 shares of Alnylam Pharmaceuticals worth $5.53M as of Q2 2026.
- Sumitomo Mitsui DS Asset Management bought 2,423 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $731K.
- Alnylam Pharmaceuticals made up 0.04% of Sumitomo Mitsui DS Asset Management's portfolio in Q2 2026, its #322 holding.
- Sumitomo Mitsui DS Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- Sumitomo Mitsui DS Asset Management's Alnylam Pharmaceuticals position peaked at $7.22M in Q3 2025.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.